Meizon Innovation
Biotechnology Research • • 1-10 Employees
Company overview
| Headquarters | XX |
| Website | |
| NAICS | 541714 |
| Founded | 2018 |
| Employees | 1-10 |
Key Contact at Meizon Innovation
Sean Cortis
Executive Director
Meizon Innovation Email Formats
Meizon Innovation uses 1 email format. The most common is {first name} (e.g., john@meizon.health), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name} | john@meizon.health | 100% |
About Meizon Innovation
DL33 and M08 are pioneering treatments aimed at and addressing neurological conditions like dementia and autism. They offer new hope for improving quality of life and advancing neurological care. “To make a difference, you must be different.” By leading with cutting-edge science and a global vision, Meizon strives to maximize health outcomes for society. Together we are bringing hope and aim to provide relief to millions around the world. Dementia and autism are global health crises impacting millions, necessitating innovative solutions for improved outcomes. Dementia affects 55 million people globally, leading to significant disability and economic costs of over US$1.3 trillion annually. Autism Spectrum Disorder impacts one in every 36 children in the US as of 2020, and expected to affect one in 25 children in Australia in 2024. Childhood Dementia accounts for 700,000 cases and 48,300 premature deaths worldwide each year.
Meizon Innovation revenue & valuation
| Annual revenue | $598,885 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $2,000,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Funding Data
Meizon Innovation has never raised funding before.
United Kingdom
United States
Canada
Frequently asked questions
4.8
40,000 users
